Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment

Japanese Journal of Clinical Immunology

Volumn 33, Issue 3, 2010, Pages 135-141

  Nozaki, Yuji ^a   Nagare, Yasuaki ^a   Hino, Shoichi ^a   Yano, Tomohiro ^a   Kishimoto, Kazuya ^a   Shimazu, Hideki ^a   Ikoma, Shinya ^a   Kinoshita, Koji ^a   Funauchi, Masanori ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical response; Infliximab; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

C REACTIVE PROTEIN; HLA DR4 ANTIGEN; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; RHEUMATOID FACTOR;

EID: 77954705908     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.33.135     Document Type: Article

References (25)

1. Maini RN, Taylor PC. : Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51 : 207-229, 2000.
2. Maini R, et al. : Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 : 1932-1939, 1999.
3. Charles P, et al. : Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163 : 1521-1528, 1999.
4. Pittoni V, et al. : Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann. Rheum. Dis. 61 : 723-725, 2002.
5. del Val del Amo N, et al. : Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis : relation with disease aggressiveness. Clin. Exp. Rheumatol. 24 : 281-286, 2006.
6. St Clair EW. : Infliximab treatment for rheumatic disease : clinical and radiological efficacy. Ann. Rheum. Dis. 61 Suppl 2 : ii67-9, 2002.
7. Plant MJ, et al. : Patterns of radiological progression in early rheumatoid arthritis : results of an 8 year prospective study. J. Rheumatol. 25 : 417-426, 1998.
8. Waaler E. : On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. APMIS. 115 : 422-438, 2007.
9. Greiner A, et al. : Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1050 : 295-303, 2005.
10. De Rycke L, et al. : Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann. Rheum. Dis. 64 : 299-302, 2005.
11. Elliott MJ, et al. : Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 36 : 1681-1690, 1993.
12. Arnett FC, et al. :The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 : 315-324, 1993.
13. Prevoo ML, et al. : Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38 : 44-48, 1995.
14. Steinbrocker O, Traeger CH, Batterman RC. : Therapeutic criteria in rheumatoid arthritis. J. Am. Med. Assoc. 140 : 659-662, 1949.
15. Drossaers-Bakker KW, et al. : Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42 : 1854-1860, 1999.
16. Fries JF, et al. : Measurement of patient outcome in arthritis. Arthritis Rheum. 23 : 137-145, 1980.
17. Goekoop-Ruiterman YP, et al. : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : a randomized, controlled trial. Arthritis Rheum. 52 : 3381-3390, 2005.
18. Wener MH. : Rheumatoid factors. In : Rose NR, et al. ed. Manual of Clinical Laboratory Immunology : American Society for Microbiology Press. 961-972, 2002.
19. Borretzen M, et al. : Rheumatoid factors. In : Peter JB, Shoenfield Y eds. Autoantibodies : Elsevier Science BV : PP706-715, 1996.
20. Alarcon GS, et al. : Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum. 33 : 1156-1161, 1990.
21. Olsen NJ, Teal GP, Brooks RH. : IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions 34 : 169-171, 1991.
22. Charles PJ, et al. : Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43 : 2383-2390, 2000.
23. Alessandri C, et al. : Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. 63 : 1218-1221, 2004.
24. Smeets TJ, et al. : Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 48 : 2155-2162, 2003.
25. Reparon-Schuijt CC, et al. : Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum. 41 : 2211-2220, 1998. (Pubitemid 29009380)